1. Armstrong DG, Lavery LA. Monitoring healing of acute Charcot's arthropathy with infrared dermal thermometry. J Rehabil Res Dev 1997a; 34: 317-21.
  2. Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 1997b; 14: 357-63.
  3. Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. J Am Podiatr Med Assoc 1997c; 87: 272-8.
  4. Bém R, Jirkovská A. Charcotova neuroosteoarthropatie. DMEV 2011;14: 181-6
  5. Bém R, Fejfarová V, Jirkovská A. Neuropatické fraktury v oblasti kolenního kloubu u pacientů s diabetem. DMEV 2006a; 9: 63-67.
  6. Bem R, Jirkovska A, Dubsky M, Fejfarova V, Buncova M, Skibova J, Jude EB. Role of Quantitative Bone Scanning in the Assessment of Bone Turnover in Patients with Charcot Foot. Diabetes Care 2010a; 33: 348-349.
  7. Bem R, Jirkovská A, Dubský M, Fejfarová V, Kožnarová R, Skibová J, Adamec M, Bouček P, Saudek F. 5-year incidence of and risk factors for Charcot neuroosteoarthropathy after pancreas transplantation (Abstract). Diabetes  2010b; 59: A323.
  8. Bem R, Jirkovská A, Dubský M, Wosková V, Fejfarová V, Skibová J. Peripheral arterial disease is not rare in diabetic patients with ulcerated charcot foot (Abstract). The Diabetic Foot Abstract Book 2011; 6: 104.
  9. Bém R, Jirkovská A, Fejfarová V, Skibova J. Long-term effects of intranasal calcitonin on healing times and recurrence of acute Charcot foot: a randomized controlled trial (Abstract). Diabetologia 2006b; 49: 99-100.
  10. Bem R, Jirkovska A, Fejfarova V, Skibova J, Jude EB. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care 2006; 29: 1392-4.
  11. Cavanagh PR, Ulbrecht JS, Caputo GM. New developments in the biomechanics of the diabetic foot. Diabetes Metab Res Rev 2000; 16 Suppl 1: S6-S10.
  12. Cavanagh PR, Young MJ, Adams JE, Vickers KL, Boulton AJ. Radiographic abnormalities in the feet of patients with diabetic neuropathy. Diabetes Care 1994; 17: 201-9.
  13. Cofield RH, Morrison MJ, Beabout JW. Diabetic neuroarthropathy in the foot: patient characteristics and patterns of radiographic change. Foot Ankle 1983; 4: 15-22.
  14. de Souza LJ. Charcot arthropathy and immobilization in a weight-bearing total contact cast. J Bone Joint Surg Am 2008; 90: 754-9.
  15. Eloesser L. On the nature of neuropathic affections of the joint. Ann Surg 1917; 66: 201.
  16. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491-8.
  17. Gazis A, Pound N, Macfarlane R, Treece K, Game F, Jeffcoate W. Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot). Diabet Med 2004; 21: 1243-6.
  18. Gold RH, Tong DJ, Crim JR, Seeger LL. Imaging the diabetic foot. Skeletal Radiol 1995; 24: 563-71.
  19. Gough A, Abraha H, Li F, Purewal TS, Foster AV, Watkins PJ, Moniz C, Edmonds ME. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 1997; 14: 527-31.
  20. Herbst SA, Jones KB, Saltzman CL. Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density. J Bone Joint Surg Br 2004; 86: 378-83.
  21. Chantelau E. The perils of procrastination: effects of early vs. delayed detection and treatment of incipient Charcot fracture. Diabet Med 2005; 22: 1707-12.
  22. Charcot JM. Sur quelques anthropathies qui paraissent dépendre dune lesion du cervean ou de la moelle épindere. Arch Physiol Norm Pathol 1868; 1: 161-178.
  23. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005; 366: 2058-61.
  24. Jirkovska A, Boucek P, Wu S, Hosova J, Bem R, Fejfarova V, Skibova J. Power spectral analysis of heart rate variability in patients with Charcot's neuroarthropathy. J Am Podiatr Med Assoc 2006; 96: 1-8.
  25. Jirkovska A, Kasalicky P, Boucek P, Hosova J, Skibova J. Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover. Diabet Med 2001; 18: 495-500.
  26. Jones EA, Manaster BJ, May DA, Disler DG. Neuropathic osteoarthropathy: diagnostic dilemmas and differential diagnosis. Radiographics 2000; 20 Spec No: S279-93.
  27. Jordan WR. Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936; 57: 307-358.
  28. Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, Donohoe M, Foster AV, Edmonds ME, Boulton AJ. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001; 44: 2032-7.
  29. Kimmerle R, Chantelau E. Weight-bearing intensity produces charcot deformity in injured neuropathic feet in diabetes. Exp Clin Endocrinol Diabetes 2007; 115: 360-4.
  30. Korzon-Burakowska A, Jakobkiewicz-Banecka J, Fiedosiuk A, Petrova N, Koblik T, Gabig-Ciminska M, Edmonds M, Malecki MT, Wegrzyn G. Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabet Med 2011 (v tisku).
  31. Kucera T, Urban K, Sponer P. Charcot arthropathy of the knee. A case-based review. Clinical rheumatology 2011; 30: 425-8.
  32. La Fontaine J, Harkless LB, Sylvia VL, Carnes D, Heim-Hall J, Jude E. Levels of endothelial nitric oxide synthase and calcitonin gene-related peptide in the Charcot foot: a pilot study. J Foot Ankle Surg 2008; 47: 424-9.
  33. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008a; 51: 1035-40.
  34. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008b; 51: 1035-40.
  35. Matricali GA, Bammens B, Kuypers D, Flour M, Mathieu C. High rate of charcot foot attacks early after simultaneous pancreas-kidney transplantation. Transplantation 2007; 83: 245-6.
  36. Mitchell JK. On a new practice in acute and chronic rheumatism. Am J Med Sci 1831; 8: 55.
  37. Pakarinen TK, Laine HJ, Maenpaa H, Mattila P, Lahtela J. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes Care 2011; 34: 1514-6.
  38. Palestro CJ, Mehta HH, Patel M, Freeman SJ, Harrington WN, Tomas MB, Marwin SE. Marrow versus infection in the Charcot joint: indium-111 leukocyte and technetium-99m sulfur colloid scintigraphy. J Nucl Med 1998; 39: 346-50.
  39. Petrova NL, Foster AV, Edmonds ME. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes. Diabet Med 2005; 22: 756-61.
  40. Petrova NL, Moniz C, Elias DA, Buxton-Thomas M, Bates M, Edmonds ME. Is there a systemic inflammatory response in the acute charcot foot? Diabetes Care 2007; 30: 997-8.
  41. Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM, Manto A, Caradonna P, Ghirlanda G. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 2005; 28: 1214-5.
  42. Pitocco D, Zelano G, Gioffre G, Di Stasio E, Zaccardi F, Martini F, Musella T, Scavone G, Galli M, Caputo S, Mancini L, Ghirlanda G. Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic charcot neuroarthropathy: a case-control study. Diabetes Care 2009; 32: 1694-7.
  43. Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999; 22: 827-31.
  44. Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH, Hartemann A, Game F, Jeffcoate W, Jirkovska A, Jude E, Morbach S, Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L. The Charcot foot in diabetes. Diabetes Care 2011; 34: 2123-9.
  45. Sanders LJ, Frykberg RG. (1991) Diabetic neuropathic osteoarthropathy: Charcot foot in The High Risk Foot in Diabetes Mellitus (Levin, M. E., O’Neal, L. W. & Bowker, J. H., eds) pp. 297–338, Churchill Livingstone, New York.
  46. Seabold JE, Flickinger FW, Kao SC, Gleason TJ, Kahn D, Nepola JV, Marsh JL. Indium-111-leukocyte/technetium-99m-MDP bone and magnetic resonance imaging: difficulty of diagnosing osteomyelitis in patients with neuropathic osteoarthropathy. J Nucl Med 1990; 31: 549-56.
  47. Sinacore DR. Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location. J Diabetes Complications 1998; 12: 287-93.
  48. Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003; 37: 225-38.
  49. Uccioli L, Sinistro A, Almerighi C, Ciaprini C, Cavazza A, Giurato L, Ruotolo V, Spasaro F, Vainieri E, Rocchi G, Bergamini A. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 2010; 33: 350-5.
  50. Young MJ, Marshall A, Adams JE, Selby PL, Boulton AJ. Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 1995; 18: 34-8.
  51. Zampa V, Bargellini I, Rizzo L, Turini F, Ortori S, Piaggesi A, Bartolozzi C. Role of dynamic MRI in the follow-up of acute Charcot foot in patients with diabetes mellitus. Skeletal Radiol 2011; 40: 991-9.


Zajímavé odkazy